Lokivetmab

Products

Lokivetmab was approved in the EU in 2017 and in many countries in 2018 in the form of a solution for injection (Cytopoint, Zoetis Belgium SA). Lokivetmab was the first monoclonal antibody to be cleared for animals. In the United States, locivetmab was approved in 2015 (Canine Atopic Dermatitis Immunotherapeutic).

Structure and properties

Lokivetmab is a caninized monoclonal antibody against IL-31.

Effects

Lokivetmab (ATCvet QD11AH91) has antipruritic properties. The effects are due to selective binding of the antibody to the canine cytokine interleukin-31, which prevents binding to the IL-31 receptor. The effect occurs after only a few hours and lasts for about 28 days. By blocking itching, dogs scratch less, resulting in improvement of the disease.

Indications

For the treatment of atopic dermatitis (neurodermatitis) in dogs.

Dosage

According to the professional information. The dosage depends on the body weight of the dog. The drug is administered subcutaneously.

Contraindications

For complete precautions, see the drug label.

Adverse effects

Possible adverse effects include hypersensitivity reactions and autoantibody formation, which reduce the effect.